News
DERM
6.24
+4.52%
0.27
Journey Medical Names Alloush COO
Dow Jones · 23h ago
Journey Medical appoints Ramsey Alloush as COO
Seeking Alpha · 1d ago
Journey Medical promotes Ramsey Alloush to COO
TipRanks · 1d ago
Journey Medical Promotes Ramsey Alloush, Currently General Counsel, To The Position Of COO
Benzinga · 1d ago
*Journey Medical Appoints Ramsey Alloush as Chief Operating Officer >DERM
Dow Jones · 1d ago
Press Release: Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Dow Jones · 1d ago
Weekly Report: what happened at DERM last week (0324-0328)?
Weekly Report · 2d ago
B.Riley Financial Sticks to Their Buy Rating for Journey Medical Corp (DERM)
TipRanks · 5d ago
Journey Medical’s Earnings Call Highlights MROSI Launch and Growth Potential
TipRanks · 5d ago
Journey Medical price target lowered to $10.50 from $11 at Alliance Global Partners
TipRanks · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
JOURNEY MEDICAL CORP <DERM.O>: ALLIANCE GLOBAL PARTNERS CUTS TARGET PRICE TO $10.5 FROM $11
Reuters · 6d ago
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, Carmax, Lockheed Martin
Reuters · 6d ago
Journey Medical Corporation Reports 2024 Financial Results
TipRanks · 6d ago
Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M
Seeking Alpha · 6d ago
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
NASDAQ · 6d ago
Journey Medical Corp reports results for the quarter ended December 31 - Earnings Summary
Reuters · 6d ago
Journey Medical reports FY24 EPS (72c) vs (21c) last year
TipRanks · 03/26 20:21
*Journey Medical 2024 Loss/Shr 72c >DERM
Dow Jones · 03/26 20:02
*Journey Medical 2024 Rev $56.1M >DERM
Dow Jones · 03/26 20:02
More
Webull provides a variety of real-time DERM stock news. You can receive the latest news about Journey Medical Corp through multiple platforms. This information may help you make smarter investment decisions.
About DERM
More
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.